Literature DB >> 23921899

Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Michelle A Erickson1, William A Banks.   

Abstract

The blood-brain barrier (BBB) plays critical roles in the maintenance of central nervous system (CNS) homeostasis. Dysfunction of the BBB occurs in a number of CNS diseases, including Alzheimer's disease (AD). A prevailing hypothesis in the AD field is the amyloid cascade hypothesis that states that amyloid-β (Aβ) deposition in the CNS initiates a cascade of molecular events that cause neurodegeneration, leading to AD onset and progression. In this review, the participation of the BBB in the amyloid cascade and in other mechanisms of AD neurodegeneration will be discussed. We will specifically focus on three aspects of BBB dysfunction: disruption, perturbation of transporters, and secretion of neurotoxic substances by the BBB. We will also discuss the interaction of the BBB with components of the neurovascular unit in relation to AD and the potential contribution of AD risk factors to aspects of BBB dysfunction. From the results discussed herein, we conclude that BBB dysfunction contributes to AD through a number of mechanisms that could be initiated in the presence or absence of Aβ pathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921899      PMCID: PMC3790938          DOI: 10.1038/jcbfm.2013.135

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  237 in total

1.  The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation.

Authors:  Peter Hortschansky; Volker Schroeckh; Tony Christopeit; Giorgia Zandomeneghi; Marcus Fändrich
Journal:  Protein Sci       Date:  2005-06-03       Impact factor: 6.725

Review 2.  Astroglia in dementia and Alzheimer's disease.

Authors:  J J Rodríguez; M Olabarria; A Chvatal; A Verkhratsky
Journal:  Cell Death Differ       Date:  2008-12-05       Impact factor: 15.828

3.  Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study.

Authors:  John M Starr; Andrew J Farrall; Paul Armitage; Brian McGurn; Joanna Wardlaw
Journal:  Psychiatry Res       Date:  2009-02-10       Impact factor: 3.222

4.  Rapid solute transport throughout the brain via paravascular fluid pathways.

Authors:  M L Rennels; O R Blaumanis; P A Grady
Journal:  Adv Neurol       Date:  1990

5.  Rapid dynamic CT scanning in primary degenerative dementia and age-matched controls.

Authors:  M W Dysken; M J Nelson; K M Hoover; M Kuskowski; R McGeachie
Journal:  Biol Psychiatry       Date:  1990-09-01       Impact factor: 13.382

6.  MAPK induces AQP1 expression in astrocytes following injury.

Authors:  Eric McCoy; Harald Sontheimer
Journal:  Glia       Date:  2010-01-15       Impact factor: 7.452

7.  Blood-brain barrier impairment in Alzheimer disease: stability and functional significance.

Authors:  G L Bowman; J A Kaye; M Moore; D Waichunas; N E Carlson; J F Quinn
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  The integrity of the blood-brain barrier in Alzheimer's disease.

Authors:  A Algotsson; B Winblad
Journal:  Acta Neurol Scand       Date:  2007-06       Impact factor: 3.209

9.  Early association of reactive astrocytes with senile plaques in Alzheimer's disease.

Authors:  C J Pike; B J Cummings; C W Cotman
Journal:  Exp Neurol       Date:  1995-04       Impact factor: 5.330

10.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

View more
  178 in total

Review 1.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

Review 2.  Microbiota and the control of blood-tissue barriers.

Authors:  Maha Al-Asmakh; Lars Hedin
Journal:  Tissue Barriers       Date:  2015-05-29

Review 3.  Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.

Authors:  Shu-Hui Xin; Lin Tan; Xipeng Cao; Jin-Tai Yu; Lan Tan
Journal:  Neurotox Res       Date:  2018-04-07       Impact factor: 3.911

Review 4.  Can Curcumin Counteract Cognitive Decline? Clinical Trial Evidence and Rationale for Combining ω-3 Fatty Acids with Curcumin.

Authors:  Julia Christina Kuszewski; Rachel Heloise Xiwen Wong; Peter Ranald Charles Howe
Journal:  Adv Nutr       Date:  2018-03-01       Impact factor: 8.701

Review 5.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

6.  ZO-1 expression is suppressed by GM-CSF via miR-96/ERG in brain microvascular endothelial cells.

Authors:  Hu Zhang; Shuhong Zhang; Jilin Zhang; Dongxin Liu; Jiayi Wei; Wengang Fang; Weidong Zhao; Yuhua Chen; Deshu Shang
Journal:  J Cereb Blood Flow Metab       Date:  2017-04-21       Impact factor: 6.200

Review 7.  TREK-king the blood-brain-barrier.

Authors:  Stefan Bittner; Tobias Ruck; Juncal Fernández-Orth; Sven G Meuth
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-21       Impact factor: 4.147

Review 8.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

9.  Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.

Authors:  André F Martins; Alexandre C Oliveira; Jean-François Morfin; Douglas V Laurents; Éva Tóth; Carlos F G C Geraldes
Journal:  J Biol Inorg Chem       Date:  2015-11-27       Impact factor: 3.358

Review 10.  Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?

Authors:  Guillermo Moya-Alvarado; Noga Gershoni-Emek; Eran Perlson; Francisca C Bronfman
Journal:  Mol Cell Proteomics       Date:  2015-12-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.